je.st
news
Tag: cancer patients
Mercks KEYTRUDA (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
2015-12-19 16:55:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
FDA Approves KEYTRUDA (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
2015-10-02 20:49:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Patients with EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression on FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab) monotherapy, the companys anti-PD-1 (programmed death receptor-1) therapy, at a dose of 2 mg/kg every three weeks, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: or
express
cell
treatment
10.02.15 -- Drug Resistance In Cancer Patients Linked To Oxygen-Bearing Molecules In Body
2015-10-01 02:20:33| drugdiscoveryonline Home Page
10/02/15 Drug Discovery Online Newsletter
Drug Resistance In Cancer Patients Linked To Oxygen-Bearing Molecules In Body, Study Finds
2015-09-30 09:19:44| drugdiscoveryonline News Articles
Increased levels of certain chemically reactive, oxygen-containing molecules in the body can cause patients to become resistant to cancer drugs such as chemotherapy, according to researchers at Georgia State University
Beer-Drinking Fox; Cancer Patient's Make-a-Wish Stolen; Whale Spotted: Nearby News
2015-09-27 00:33:14| Biotech - Topix.net
The Centers For Disease Control and Prevention has released the latest data on nationwide adult obesity for all 50 states. The court found that ex-tax collector Karen Guillet engaged in theft and she was therefore charged with treble damages.